Diagnostics News and Research

RSS

Patent claims for technology to assess Parkinson’s disease issued to Great Lakes Neurotechnologies

Great Lakes NeuroTechnologies announced today that the U.S. Patent Office has issued claims under patent number 8,187,209 covering their Movement Disorder Monitoring System and Method for quantitative assessment of motor symptoms associated with movement disorders.

6 Jun 2012

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott today announced results from the open-label extension of the Phase 3 ABILITY-1 investigational study of HUMIRA (adalimumab), which assessed the improvement in signs and symptoms of disease for patients with active axial spondyloarthritis (axSpA) who have no X-ray evidence of structural damage.

6 Jun 2012

Transgenomic introduces ICE COLD-PCR mutation detection technology

Transgenomic, Inc. today announced the commercial launch of its ICE COLD-PCR mutation detection technology, a breakthrough technology enabling unmatched sensitivity and complete DNA mutation detection using the standard sequencing equipment already installed in laboratories around the world.

6 Jun 2012

Abbott commences elagolix Phase 3 trial in endometriosis

Abbott, in cooperation with Neurocrine Biosciences, Inc., today announced the initiation of a pivotal Phase 3 clinical trial designed to evaluate the safety and efficacy of elagolix in female patients with endometriosis.

6 Jun 2012

GE Healthcare acquires XPRO

Today, GE Healthcare announced the acquisition of XPRO, a Brazilian Interventional X-ray equipment manufacturer company with over 15 years of experience and with more than 120 systems installed at private customer sites.

6 Jun 2012

HDL to offer testing services based on Critical Diagnostics' Presage ST2 Assay

Critical Diagnostics, a U.S.-based biomarker company focused on cardiovascular diseases and Health Diagnostic Laboratory, Inc. (HDL, Inc.), announced today an agreement under which HDL, Inc. will soon offer ST2 testing services based on Critical Diagnostics' Presage ST2 Assay.

5 Jun 2012

Advaxis to update preliminary data on ADXS-HPV Phase 2 trial for cervical cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, will update preliminary data on the safety and clinical benefit of ADXS-HPV from an ongoing randomized Phase 2 trial of ADXS-HPV with or without cisplatin in Indian women with recurrent/refractory cervical cancer who have failed cytotoxic therapy in a poster titled "ADXS11-001 immunotherapy targeting HPV-E7: Preliminary survival data from a phase II study in Indian women with recurrent/refractory cervical cancer" at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, on Sunday, June 3, 2012.

4 Jun 2012

Study shows valuable role of Mammostrat in assessing ER+ postmenopausal breast cancer patients

GE Healthcare today announced results from the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial at the 2012 Annual Meeting of the American Society of Clinical Oncology.

4 Jun 2012

Affibody, GE Healthcare partner to develop Her2-targeted PET imaging agent

GE Healthcare signed an agreement with Affibody AB to collaborate on the development of a Her2-targeted PET imaging agent, which is scheduled to begin clinical trials later this year.

4 Jun 2012

New molecular test panel to enhance reliability of thyroid biopsy testing

Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, today announced a new molecular test panel designed to help physicians determine if a thyroid gland is cancerous and requires surgical removal.

From Quest Diagnostics 2 Jun 2012

Engineered proteins demonstrate flu-fighting potency

Computer-designed proteins are under construction to fight the flu. Researchers are demonstrating that proteins found in nature, but that do not normally bind the flu, can be engineered to act as broad-spectrum antiviral agents against a variety of flu virus strains, including H1N1 pandemic influenza.

2 Jun 2012

Researchers identify chromosomal make-up of human eggs

In a groundbreaking study, Yale School of Medicine researchers and colleagues at the University of Oxford have identified the chromosomal make-up of a human egg. This discovery may soon allow them to avoid using abnormal - or aneuploid - eggs during infertility treatments, and instead to pick eggs that are healthy enough for a successful in vitro fertilization (IVF) cycle.

2 Jun 2012

Agendia launches ColoPrint microarray-based 18-gene expression signature for colon cancer

Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the launch of its ColoPrint microarray-based 18-gene expression signature for predicting the risk of distant recurrence for stage II colon cancer patients who have undergone surgery.

2 Jun 2012

Promega launches novel luciferase more versatile than current bioluminescent enzyme

Promega Corporation announces the launch of a novel luciferase that is smaller, brighter, and more versatile than any current bioluminescent enzyme. These attributes of the NanoLuc Luciferase provide new capabilities in reporter assays with potential in biologically complex applications that require greater sensitivity.

1 Jun 2012

N-of-One develops unique knowledge integration platform for oncologists

N-of-One, Inc., provider of Diagnostic Strategy Roadmaps and Treatment Strategy Roadmaps for personalized cancer care, announced today that the company has developed a unique knowledge integration platform to enable care providers and patients to make informed decisions about diagnostic and treatment strategy.

1 Jun 2012

Kindstar, Insight Genetics collaborate to improve cancer care in China

Molecular diagnostics company Insight Genetics and Kindstar Globalgene Technology, Inc., China's leading diagnostics company, today announced that the companies are partnering to enhance cancer care in the People's Republic of China and surrounding regions.

1 Jun 2012

Ventana, leading cancer researchers partner to commercialize novel IHC primary antibody

Ventana Medical Systems, Inc., a member of the Roche Group, has signed an exclusive license agreement with the German Cancer Research Center and University Hospital Heidelberg, Germany to commercialize a novel immunohistochemistry (IHC) primary antibody developed by researchers Andreas von Deimling, MD, Hanswalter Zentgraf, PhD and David Capper, MD, to detect the V600E BRAF mutation protein.

1 Jun 2012

Illumina launches Nextera XT DNA Sample Preparation Kits

Illumina today introduced the Nextera XT DNA Sample Preparation Kit, the easiest way for researchers to prepare and sequence small genomes, PCR amplicons, and plasmids.

From Illumina, Inc. 1 Jun 2012

ForteBio introduces new biosensor for use on Octet and BLItz instrumentation platforms

ForteBio, a division of Pall Life Sciences and a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the introduction of its Dip and Read Ni-NTA biosensor for use on its Octet and BLItz instrumentation platforms.

1 Jun 2012

Life Technologies, OpGen enter collaboration on Whole Genome Mapping and Ion Torrent sequencing

Life Technologies Corporation and OpGen, Inc., a commercial stage whole genome analysis company, today announced that they have signed a collaboration agreement to develop systems, technologies and applications intended to improve the management and surveillance of microbial outbreaks in the public health and infectious disease markets.

31 May 2012

Diagnostics News and Research

Patent claims for technology to assess Parkinson’s disease issued to Great Lakes Neurotechnologies

Abbott announces results from HUMIRA Phase 3 study on axSpA

Transgenomic introduces ICE COLD-PCR mutation detection technology

Abbott commences elagolix Phase 3 trial in endometriosis

GE Healthcare acquires XPRO

HDL to offer testing services based on Critical Diagnostics' Presage ST2 Assay

Advaxis to update preliminary data on ADXS-HPV Phase 2 trial for cervical cancer

Study shows valuable role of Mammostrat in assessing ER+ postmenopausal breast cancer patients

Affibody, GE Healthcare partner to develop Her2-targeted PET imaging agent

New molecular test panel to enhance reliability of thyroid biopsy testing

Engineered proteins demonstrate flu-fighting potency

Researchers identify chromosomal make-up of human eggs

Agendia launches ColoPrint microarray-based 18-gene expression signature for colon cancer

Promega launches novel luciferase more versatile than current bioluminescent enzyme

N-of-One develops unique knowledge integration platform for oncologists

Kindstar, Insight Genetics collaborate to improve cancer care in China

Ventana, leading cancer researchers partner to commercialize novel IHC primary antibody

Illumina launches Nextera XT DNA Sample Preparation Kits

ForteBio introduces new biosensor for use on Octet and BLItz instrumentation platforms

Life Technologies, OpGen enter collaboration on Whole Genome Mapping and Ion Torrent sequencing

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News